Navigation Links
Mitotech Initiates Phase 3 Clinical Trial of SkQ1 Ophthalmic Solution in Patients with Dry Eye Disease in a Co-Development Effort with Essex Bio-Technology
Date:10/24/2018

Mitotech S.A., a Luxembourg-based clinical-stage biotechnology company developing novel small molecules targeting mitochondria, today announced initiation of a U.S. Phase 3 clinical trial of SkQ1 compound in patients with moderate to severe Dry Eye Disease (DED). SkQ1 was engineered specifically for reducing oxidative stress within the mitochondria. Visomitin, a topical ophthalmic formulation of this innovative molecule, is the most advanced product from company’s line-up of products developed for treatment of a variety of age-related eye disorders, including DED.

"Very few drugs with truly innovative mechanisms of action reach this stage of clinical development in dry eye”, said Natalia Perekhvatova, Chief Executive Officer of Mitotech S.A.. “We are delighted to release the drug to clinical sites today and we are looking forward to the first visit of our first patient that is planned for this coming weekend. Dry Eye Disease is a significantly underserved indication and our company is hoping that this particular study will help deliver a break-through product to patients suffering from moderate to severe DED. Dry eye is a multifactorial disease that requires treatment featuring multifactorial mechanism of action, which Visomitin has potential to provide.”

Mitotech’s previous US clinical study was a Phase 2 trial of Visomitin with 90 patients enrolled at a single center. In that study SkQ1 demonstrated statistically significant superiority over placebo for several endpoints such as fluorescein staining, ocular discomfort and grittiness. SkQ1 was comfortable, well tolerated and there were no unexpected or serious ocular adverse events.

The upcoming Phase 3 study is a multi-center, randomized, double-blind, placebo-controlled clinical study involving three treatment arms: two concentrations of SkQ1 and placebo administered BID. Top line results are expected to be released in the second quarter of 2019.
Mitotech S.A. initiated this pivotal study as part of its co-development partnership with Essex Bio-Technology.

“We share the excitement with Mitotech in initiating the first Phase III clinical trial for both companies in the United States, with both teams putting in hard work in making the trial possible” said Malcolm Ngiam, President of Essex Bio-Investment, “An important milestone for both companies, in particular for Essex Bio-Technology as we are one step closer to operating beyond our main market in China, in the field of Ophthalmology.”

About Mitotech S.A
Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria targeting cardiolipin peroxidation inhibitors. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases. Mitotech successfully completed Phase 2 clinical study for Dry Eye indication in the U.S. with other indications also approaching clinical stage of development.

About Essex Bio-Technology
Essex Bio-Technology Limited is a bio-pharmaceutical company, started in early 90’s, a pioneer in bio-pharmaceutical industry in China, that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF, a basic fibroblast growth factor, with established mechanism of action in cellular proliferation, differentiation and migration. The Company maintains a pipeline of multi-project in R&D and on various stages of clinical programs, of which several projects involving growth factors and antibody and a handful of projects are on unit dose for Ophthalmic and Respiratory disease.

Read the full story at https://www.prweb.com/releases/mitotech_initiates_phase_3_clinical_trial_of_skq1_ophthalmic_solution_in_patients_with_dry_eye_disease_in_a_co_development_effort_with_essex_bio_technology/prweb15857173.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
2. China National Genebank initiates collaboration to sequence transcriptomes of 1,000 fish species
3. Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform
4. CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
5. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
6. Carnegie Mellon neuroscientists discover new phase of synaptic development
7. New sickle cell anemia therapy advances to Phase II clinical trials
8. Biozoom Enters Into Commercial Phase of Scanner Production
9. Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma
10. TGen and Scottsdale Healthcare launch Phase I Thunder God vine trial for cancer
11. NIH launches first phase of microbiome cloud project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2019)... ... , ... X-ray analytical instrument manufacturer Rigaku Corporation is pleased to ... ( TSM ). The event is hosted by the Kleberg Advanced Microscopy Center at ... 2019. Several workshops are scheduled, as well as a scientific program with platform and ...
(Date:2/19/2019)... ... February 20, 2019 , ... ... agreement that will see Dimensions rolled out across the organization. Dimensions provides ... decisions across their business, support strategic planning, and understand past and future ...
(Date:2/19/2019)... ... ... Emma came home from her first day of elementary school with a long list of ... there to make her homework a little more fun. Unable to find anything suitable, he ... simple enough: help children learn the vocabulary they see in school — not just the ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... ... webinar will review strategies for data management in modular and adaptive clinical trials. , ... up to 30 percent, reducing cost while increasing quality, achieving clinical site set-up faster , ... data – reducing risk and impact on trial success, trial teams, and trial execution , ...
(Date:3/19/2019)... ... March 19, 2019 , ... Cirrascale ... announced it has begun offering NVIDIA® DGX-1™ deep learning systems as part of ... to provide the highest performance for artificial intelligence and deep learning research and ...
(Date:3/15/2019)... ATLANTA (PRWEB) , ... March ... ... acquisition of 100% equity in American Process Inc. and affiliate companies including ... Alpena Biorefinery in Alpena Michigan, the Thomaston Biorefinery and R&D center in ...
(Date:3/14/2019)... ... 2019 , ... The growth in the number and complexity of regulations as ... Regulatory intelligence (RI) systems are not keeping ... Insights faster and cheaper. With a diversity of information sources, identifying and analyzing context ...
Breaking Biology Technology: